Edition:
United Kingdom

People: Omeros Corp (OMER.OQ)

OMER.OQ on NASDAQ Stock Exchange Global Market

18.52USD
18 Apr 2019
Change (% chg)

$-0.41 (-2.17%)
Prev Close
$18.93
Open
$18.91
Day's High
$19.02
Day's Low
$18.42
Volume
109,141
Avg. Vol
205,595
52-wk High
$27.00
52-wk Low
$10.30

Kirby, Daniel 

Mr. Daniel Kirby is Vice President and Head of Commercial of the company. Mr. Kirby assumes the role of vice president and head of commercial at Omeros, having joined the company from Celgene. At Celgene, he was the U.S. commercial lead for its chimeric antigen receptor (CAR) T-cell franchise. Before its acquisition by Celgene, Mr. Kirby built and led the commercial marketing and market access functions in his role as vice president and head of marketing/market access at Juno Therapeutics. Prior to Juno, he was the head of marketing at Medivation where he oversaw all of the marketing efforts for the blockbuster Xtandi ® . Mr. Kirby previously spent nearly 15 years in both marketing and sales leadership roles at Amgen, including oversight of all U.S. customer-facing marketing efforts for its multi-billion-dollar granulocyte colony-stimulating factor (G-CSF) franchise NEULASTA ® and NEUPOGEN ® . Before joining Amgen, he advanced through commercial positions of increasing responsibility at GlaxoSmithKline

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Gregory Demopulos

4,535,280

Michael Jacobsen

1,016,330

Marcia Kelbon

1,219,050

Daniel Kirby

--

Justin McCue

--

Thomas Cable

106,050
As Of  31 Dec 2017